Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Nanjo, Shigeki ^a   Yamada, Tadaaki ^a   Nishihara, Hiroshi ^b   Takeuchi, Shinji ^a   Sano, Takako ^a   Nakagawa, Takayuki ^a   Ishikawa, Daisuke ^a   Zhao, Lu ^a   Ebi, Hiromichi ^a   Yasumoto, Kazuo ^a   Matsumoto, Kunio ^a   Yano, Seiji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; WZ 4002; ACRYLAMIDE DERIVATIVE; EGFR PROTEIN, HUMAN; MET PROTEIN, HUMAN; N [3 [[5 CHLORO 2 [[2 METHOXY 4 (4 METHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL]OXY]PHENYL]ACRYLAMIDE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENZYME PHOSPHORYLATION; FEASIBILITY STUDY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA; LOW DRUG DOSE; LUNG ADENOCARCINOMA; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MONOTHERAPY; MOUSE; MUCOSAL DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WEIGHT REDUCTION; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; METABOLISM; MISSENSE MUTATION; PATHOLOGY; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL LINE;

ACRYLAMIDES; AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; MUTATION, MISSENSE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891333707     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084700     Document Type: Article

References (37)

1. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10: 760-774. doi:10.1038/nrc2947. PubMed: 20966921.
2. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S et al. (2013) Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve nonsmall cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 24: 54-49. doi:10.1093/annonc/mdt459.103. PubMed: 22967997.
3. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128. doi:10.1016/S1470-2045(09)70364-X. PubMed: 20022809.
4. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246. doi:10.1016/S1470-2045(12)70227-9. PubMed: 22285168.
5. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V et al. (2013) Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol 31(27):3327-34. PubMed: 23816960.
6. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824. doi:10.1111/j.1349-7006.2007.00607.x. PubMed: 17888036. (Pubitemid 350002184)
7. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792. doi:10.1056/NEJMoa044238. PubMed: 15728811. (Pubitemid 40271173)
8. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73. doi:10.1371/journal.pmed.0020073. PubMed: 15737014.
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. doi:10.1126/science.1141478. PubMed: 17463250. (Pubitemid 46799492)
10. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H et al. (2008) Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68: 9479-9487. doi: 10.1158/0008-5472.CAN-08-1643. PubMed: 19010923.
11. Zhang Z, Lee JC, Lin L, Olivas V, Au V et al. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44: 852-860. doi:10.1038/ng.2330. PubMed: 22751098.
12. Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V et al. (2011) Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced nonsmall cell lung cancer. J Thorac Oncol 6: 707-715. doi:10.1097/JTO.0b013e31820a3a6b. PubMed: 21258250.
13. Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M et al. (2010) Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 70: 8715-8725. doi:10.1158/0008-5472. CAN-10-0043. PubMed: 20959484.
14. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26. PubMed: 21430269.
15. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H et al. (2011) Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6: 1152-1161. doi:10.1097/JTO.0b013e318216ee52. PubMed: 21597390.
16. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105: 2070-2075. doi:10.1073/pnas.0709662105. PubMed: 18227510. (Pubitemid 351439466)
17. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA et al. (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102: 7665-7670. doi:10.1073/pnas. 0502860102. PubMed: 15897464. (Pubitemid 40741028)
18. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK et al. (2005) An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65: 7096-7101. doi: 10.1158/0008-5472.CAN- 05-1346. PubMed: 16103058. (Pubitemid 41161238)
19. Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC et al. (2007) Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res 67: 10417-10427. doi:10.1158/0008-5472.CAN-07-1248. PubMed: 17974985. (Pubitemid 350070817)
20. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ et al. (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67: 11924-11932. doi: 10.1158/0008-5472.CAN-07-1885. PubMed: 18089823.
21. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-4711. doi:10.1038/onc.2008.109. PubMed: 18408761.
22. Zhou W, Ercan D, Chen L, Yun CH, Li D et al. (2009) Novel mutantselective EGFR kinase inhibitors against EGFR T790M. Nature 462: 1070-1074. doi:10.1038/nature08622. PubMed: 20033049.
23. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D et al. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88. doi:10.1016/j.ccr.2009.11.022. PubMed: 20129249.
24. Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y et al. (2010) Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 16: 174-183. doi: 10.1158/1078-0432.CCR-09-1204. PubMed: 20008840.
25. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y et al. (2011) Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6: 2011-2017. doi:10.1097/JTO.0b013e31823ab0dd. PubMed: 22052230.
26. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703. doi:10.1056/NEJMoa1006448. PubMed: 20979469.
27. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H et al. (2010) Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16: 5489-5498. doi: 10.1158/1078-0432.CCR-10-1371. PubMed: 21062933.
28. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105: 2070-2075. doi:10.1073/pnas.0709662105. PubMed: 18227510. (Pubitemid 351439466)
29. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M et al. (1989) Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443. doi:10.1038/342440a0. PubMed: 2531289. (Pubitemid 19277521)
30. Nishioka Y, Yano S, Fujiki F, Mukaida N, Matsushima K et al. (1997) Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance. Int J Cancer 71: 170-177. doi:10.1002/(SICI)1097-0215(19970410)71:2. PubMed: 9139838. (Pubitemid 27252986)
31. Green LM, Reade JL, Ware CF (1984) Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods 70: 257-268. doi: 10.16/0022-1759(84)90190-X. PubMed: 6609997. Available online at: doi:10.1016/0022-1759(84)90190-X Available online at: PubMed: 6609997 (Pubitemid 14111307)
32. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K et al. (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13: 528-538. doi:10.1016/S1470-2045(12)70087-6. PubMed: 22452896.
33. Xu L, Kikuchi E, Xu C, Ebi H, Ercan D et al. (2012) Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 72: 3302-3311. doi:10.1158/1538-7445.AM2012-3302. PubMed: 22552292.
34. Matsumoto K, Nakamura T (2006) Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 119: 477- 483. doi:10.1002/ijc.21808. PubMed: 16453287. (Pubitemid 43955698)
35. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I et al. (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119: 3000-3010. PubMed: 19759520. Available online at: PubMed: 19759520
36. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E et al. (2008) Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 68: 5827-5838. doi: 10.1158/0008-5472.CAN-07-5428. PubMed: 18632637.
37. Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S et al. (2013) The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Int J Cancer 133: 505-514. doi:10.1002/ijc.28034. PubMed: 23319394.